conversion of semaglutide to tirzepatide Dose-equivalence reference based on pivotal GLP-1/dual-agonist trials: SURMOUNT-1 (tirzepatide/Zepbound, 72 weeks) STEP-1 (subcutaneous semaglutide/Wegovy, 68 weeks) OASIS-4 (oral semaglutide/Wegovy, 64 weeks). For educational comparison only—these are Switching from Semaglutide to Tirzepatide

Xu X, Bellucci KSW, Elenitsas R, Elder DE

Oral Supplements This comparison illustrates that neither approach universally surpasses the otherthe optimal choice depends on individual circumstances, health status, and specific goals

However, they are being discussed within the medical community because they act on biological systems that are involved in many of the changes that occur during perimenopause and menopause

The practical version of the right question is whether you should consider an off-label semaglutide or tirzepatide trial for AUD now, given the existing data, rather than waiting for the on-label option in 2029